Shares of Organovo Holdings Inc (NASDAQ:ONVO) have been assigned an average recommendation of “Hold” from the eight analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $3.94.

A number of research firms recently weighed in on ONVO. Jefferies Group reissued a “buy” rating and issued a $4.00 target price on shares of Organovo in a report on Tuesday, September 26th. Zacks Investment Research raised shares of Organovo from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Wednesday, October 11th. Raymond James Financial lowered shares of Organovo from an “outperform” rating to a “market perform” rating and set a $5.00 target price for the company. in a report on Friday, November 10th. Citigroup lowered shares of Organovo to a “market perform” rating in a report on Friday, November 10th. Finally, BTIG Research restated a “buy” rating and issued a $3.00 price target on shares of Organovo in a research report on Thursday, November 16th.

Organovo (ONVO) opened at $1.39 on Tuesday. Organovo has a fifty-two week low of $1.32 and a fifty-two week high of $3.85. The firm has a market cap of $148.62, a price-to-earnings ratio of -3.66 and a beta of 3.08.

Organovo (NASDAQ:ONVO) last posted its earnings results on Thursday, November 9th. The medical research company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Organovo had a negative net margin of 923.89% and a negative return on equity of 65.63%. The firm had revenue of $1.36 million during the quarter, compared to analyst estimates of $1.38 million. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. analysts anticipate that Organovo will post -0.36 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of ONVO. Schwab Charles Investment Management Inc. lifted its position in Organovo by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 388,300 shares of the medical research company’s stock worth $1,022,000 after buying an additional 2,641 shares during the last quarter. Rhumbline Advisers lifted its position in Organovo by 4.4% in the second quarter. Rhumbline Advisers now owns 110,444 shares of the medical research company’s stock worth $290,000 after buying an additional 4,640 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Organovo by 1.0% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 91,204 shares of the medical research company’s stock worth $240,000 after buying an additional 890 shares during the last quarter. Alliancebernstein L.P. lifted its position in Organovo by 27.4% in the second quarter. Alliancebernstein L.P. now owns 93,050 shares of the medical research company’s stock worth $245,000 after buying an additional 20,000 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in Organovo by 40.9% in the second quarter. Teachers Advisors LLC now owns 235,489 shares of the medical research company’s stock worth $619,000 after buying an additional 68,412 shares during the last quarter. Institutional investors own 25.78% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Organovo Holdings Inc (ONVO) Receives Consensus Rating of “Hold” from Brokerages” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/16/organovo-holdings-inc-onvo-receives-consensus-rating-of-hold-from-brokerages.html.

About Organovo

Analyst Recommendations for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.